Brady Kelly 4

What Happened

• Brady Kelly, Chief Operating Officer and Executive Vice President of Seres Therapeutics (MCRB), had 180 restricted stock units (RSUs) vest and convert into 180 shares on May 15, 2026. Those 180 shares were disposed (withheld) to cover taxes, and he separately sold 59 shares in the open market on May 18, 2026 for $7.53 per share (proceeds $444).

Key Details

• Transaction dates and prices:
  • 2026-05-15: 180 RSUs converted to 180 shares (derivative conversion/exercise; acquisition reported as N/A).
  • 2026-05-15: 89 shares and 91 shares reported disposed at $0.00 each (share withholding/surrender to cover taxes).
  • 2026-05-18: Open-market sale of 59 shares at $7.53/share for total proceeds of $444.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes of note:
  • F1: Each RSU equals one share of common stock.
  • F2: The $0 disposals represent shares sold/withheld to cover tax withholding on vesting.
  • F3/F4: The RSUs follow a vesting schedule (25% initial vest, remainder in 12 quarterly installments); RSUs have no expiration.
• Filing timeliness: Report covers transactions dated May 15–18, 2026 and was filed May 19, 2026 — filed within the standard two business-day window (timely).

Context

• This is primarily a compensation-related transaction: RSUs vested and were settled, with shares withheld to cover taxes (a routine administrative step). The separate open-market sale of 59 shares was small (about $444) and does not, by itself, imply a strong trading signal. The derivative entries at $0 typically indicate share surrender/withholding rather than a market sale for cash.